Cargando…

BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia

High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom’s macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of BCNU, etoposide, cytarabine, and melphalan, is ofte...

Descripción completa

Detalles Bibliográficos
Autores principales: Heini, Alexander D., Beck, Philipp, Bacher, Ulrike, Seipel, Katja, Zander, Thilo, Daskalakis, Michael, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057504/
https://www.ncbi.nlm.nih.gov/pubmed/36983378
http://dx.doi.org/10.3390/jcm12062378
_version_ 1785016383784878080
author Heini, Alexander D.
Beck, Philipp
Bacher, Ulrike
Seipel, Katja
Zander, Thilo
Daskalakis, Michael
Pabst, Thomas
author_facet Heini, Alexander D.
Beck, Philipp
Bacher, Ulrike
Seipel, Katja
Zander, Thilo
Daskalakis, Michael
Pabst, Thomas
author_sort Heini, Alexander D.
collection PubMed
description High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom’s macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of BCNU, etoposide, cytarabine, and melphalan, is often used as a conditioning regimen. However, problems with BCNU, including pneumotoxicity, tolerance, and availability, necessitate the search for alternatives. In this pilot study, we investigated high-dose chemotherapy with BeEAM, in which BCNU is replaced with high-dose bendamustine as an alternative conditioning regimen in six subsequent patients with WM. Bendamustine treatment was well tolerated without unexpected toxicities. The overall response rate was 6/6 patients (2 very good partial responses (VGPR) and 4 PR). After a median follow-up of 72 months, two (33%) patients relapsed. Median progression-free and overall survivals were not reached, and no severe late-onset toxicities were observed so far. In this pilot study, BeEAM conditioning before ASCT seems feasible, safe, and effective in patients with WM.
format Online
Article
Text
id pubmed-10057504
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100575042023-03-30 BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia Heini, Alexander D. Beck, Philipp Bacher, Ulrike Seipel, Katja Zander, Thilo Daskalakis, Michael Pabst, Thomas J Clin Med Article High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom’s macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of BCNU, etoposide, cytarabine, and melphalan, is often used as a conditioning regimen. However, problems with BCNU, including pneumotoxicity, tolerance, and availability, necessitate the search for alternatives. In this pilot study, we investigated high-dose chemotherapy with BeEAM, in which BCNU is replaced with high-dose bendamustine as an alternative conditioning regimen in six subsequent patients with WM. Bendamustine treatment was well tolerated without unexpected toxicities. The overall response rate was 6/6 patients (2 very good partial responses (VGPR) and 4 PR). After a median follow-up of 72 months, two (33%) patients relapsed. Median progression-free and overall survivals were not reached, and no severe late-onset toxicities were observed so far. In this pilot study, BeEAM conditioning before ASCT seems feasible, safe, and effective in patients with WM. MDPI 2023-03-19 /pmc/articles/PMC10057504/ /pubmed/36983378 http://dx.doi.org/10.3390/jcm12062378 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Heini, Alexander D.
Beck, Philipp
Bacher, Ulrike
Seipel, Katja
Zander, Thilo
Daskalakis, Michael
Pabst, Thomas
BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
title BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
title_full BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
title_fullStr BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
title_full_unstemmed BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
title_short BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
title_sort beeam conditioning including high-dose bendamustine before autologous stem cell transplantation is safe and effective in patients with waldenstrom’s macroglobulinemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057504/
https://www.ncbi.nlm.nih.gov/pubmed/36983378
http://dx.doi.org/10.3390/jcm12062378
work_keys_str_mv AT heinialexanderd beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia
AT beckphilipp beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia
AT bacherulrike beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia
AT seipelkatja beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia
AT zanderthilo beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia
AT daskalakismichael beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia
AT pabstthomas beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia